Drugs / NEVADISTINEL
NEVADISTINEL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04148391 | Nov 2019 → Dec 2022 overdue | Lewy body dementia, Parkinson disease, cognitive impairment with or without cerebellar ataxia | Aptinyx | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEVADISTINEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314586 ↗ |
| Known as | NYX-3054 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314586 ↗ |
| Known as | NYX-458 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04148391 ↗ |
| Modality | Small molecule | “NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).” NCT04148391 ↗ |
| Route | Oral | “Single oral dose taken daily for 12 weeks.” NCT04148391 ↗ |